Trial-Results center  
Clinical trial results database in cardiology Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

coronary artery disease - Drug eluting stent - acute myocardial infarction

coronary artery disease - Drug eluting stent - all type of patients


Related trials

BASKET-PROVE (SES), 2010 - sirolimus eluting stent vs bare-metal stent

GISSOC II, 2010 - sirolimus eluting stent vs bare-metal stent

RESOLUTE All comers, 2010 - zotarolimus eluting stent vs everolimus eluting stent

SORT-OUT-3, 2010 - zotarolimus eluting stent vs sirolimus eluting stent

SPIRIT IV, 2010 - everolimus eluting stent vs paclitaxel eluting stent

BASKET-PROVE (EES), 2010 - everolimus eluting stent vs bare-metal stent

ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol eluting stent vs zotarolimus eluting stent

Thiele, 2009 - sirolimus ES vs MIDCAB

ENDEAVOR IV, 2009 - zotarolimus eluting stent vs paclitaxel eluting stent

ZEST AMI (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent

COMPARE, 2009 - everolimus eluting stent vs paclitaxel eluting stent

ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol eluting stent vs sirolimus eluting stent

ZEST (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent

ZEST (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent

ISAR TEST 3 (BP), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent

ISAR-TEST-4 (biodegradable polymer), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent

GENIUS-STEMI, 2009 - Genous stent vs bare-metal stent

SYNTAX, 2009 - paclitaxel eluting stent vs CABG

PASEO, 2009 - drug-eluting stents vs bare-metal stent

ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus eluting stent

DEBATER (SES vs BMS), 2009 - sirolimus eluting stent vs bare-metal stent

ISAR-LEFT-MAIN, 2009 - sirolimus eluting stent vs paclitaxel eluting stent

ZEST AMI (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent

SORT OUT II, 2008 - sirolimus eluting stent vs paclitaxel eluting stent

DES-DIABETES, 2008 - sirolimus eluting stent vs paclitaxel eluting stent



See also:

  • All coronary artery disease clinical trials
  • All clinical trials of Drug eluting stent
  • All clinical trials of zotarolimus eluting stent
  •  

    SORT-OUT-3 study, 2010

    download pdf: zotarolimus eluting stent | Drug eluting stent for coronary artery disease

    Treatments

    Studied treatment Zotarolimus-eluting stents
    Endeavor
    Control treatment sirolimus-eluting stents (SES)
    Cypher
    Concomittant treatment dual antiplatelet therapy for 12 months

    Patients

    Patients Patients With Coronary Artery Disease undergoing PCI for any indication
    Exclusion criteria inability to provide informed consent; life expectancy <1 year; allergy to aspirin or clopidogrel; participation in another tria
    Baseline characteristics
    age 64.3% 
    history of MI (%) 26.5% 
    diabetes (%) 14% 
    unstable angina (%) 38% 
    lesion length (mm) 13.5 mm 
    male (%) 72.5% 
    Female (%) 26% 
    STEMI 7% 
    Stable angina 52% 
    No of lesions per patients 1.55 

    Method and design

    Randomized effectives 1162 / 1171 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 9 months (18 mo)
    Hypothesis Superiority
    Primary endpoint MACE


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    All cause death

    NA / 1162
    NA / 1171
    classic 1,45 [0,76;2,77]

    cardiac death

    NA / 1162
    NA / 1171
    classic 1,51 [0,73;3,13]

    MI (fatal and non fatal)

    NA / 1162
    NA / 1171
    classic 3,47 [1,15;10,48]

    target lesion revascularisation

    NA / 1162
    NA / 1171
    classic 4,19 [2,12;8,28]

    Stent thrombosis (any, end of follow up)

    NA / 1162
    NA / 1171
    classic 4,62 [1,34;15,93]

    2 yr Death (all cause)

    NA / 1162
    NA / 1171
    classic 1,61 [1,03;2,51]

    2 yr MACE

    NA / 1162
    NA / 1171
    classic 2,19 [1,58;3,04]

    2 yr TLR

    NA / 1162
    NA / 1171
    classic 3,66 [2,23;6,01]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.

    Meta-analysis of all similar trials:

    Drug eluting stent in coronary artery disease for acute myocardial infarction

    Drug eluting stent in coronary artery disease for all type of patients



    Reference(s)

    Trials register # NA
    • Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbæk H, Tilsted HH, Abildgaard U, Christiansen EH, Engstrøm T, Krusell LR, Ravkilde J, Hansen PR, Hansen KN, Abildstrøm SZ, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Madsen M, Johnsen SP, Jensen LO, Søren. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.. Lancet 2010 Mar 13;: - 10.1016/S0140-6736(10)60208-5
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend